Bo Kara will take over VP of Process Development and Simon Dew will be VP of Business Development
New VP of Process Development, Bo Kara
Evox Therapeutics, an exosome therapeutics company, has appointed two new VPS. Bo Kara has been made VP of Process Development and Simon Dew as VP of Business Development.
Kara has over 30 years’ experience in the biotech industry. He joins Evox from his position as Head of Process Development at GlaxoSmithKline’s cell & gene therapy division.
To the Process Development team, Kara brings with him extensive experience in product development. At GlaxoSmithKline, he was responsible for all aspects of process development, the implementation of manufacturing strategies, and oversaw development across the full commercialisation process from pre-candidate through to post-commercial support. Prior to this, he spent eight years as Director of Science and Technology at Fujifilm Diosynth Biotechnologies, and also held roles at AstraZeneca.
Dew has joined Evox from Gyroscope Therapeutics where he held the position of VP of Corporate Strategy. In this role, he developed medium- to long-term value generating strategies while helping to expand the pipeline and evaluate potential new therapeutic areas. Over the past 25 years, he has held a number of business and corporate development roles at Astellas Pharmaceuticals, Quintiles Transnational, PAREXEL International, Phytopharm, SmithKline Beecham and Bristol Myers Squibb.
Commenting on the appointments, Dr Antonin de Fougerolles, CEO of Evox, said: “The appointment of these two highly regarded and experienced executives reflects the continued growth of Evox Therapeutics. As we enter the next stage of our development, we will look to use the knowledge and expertise that both Bo and Simon bring to guide us in advancing a pipeline of exosome therapeutics both for ourselves and for partners.”